Know Cancer

or
forgot password


N/A
N/A
N/A
Open (Enrolling)
Both
Metastatic Colorectal Cancer

Thank you

Trial Information


Inclusion Criteria:



- histologically confirmed metastatic colorectal cancer patients Having initiated
treatment with bevacizumab

Exclusion Criteria:

- non-metastatic colorectal cancer patients not recieved bevacizumab

Type of Study:

Observational [Patient Registry]

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

Objective response rate

Outcome Description:

To evaluate the treatment response of bevacizumab in Chinese patients with mCRC in real clinical practice

Outcome Time Frame:

6 weeks

Safety Issue:

No

Principal Investigator

Lin Shen, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Beijing Cancer Hopital

Authority:

China: Food and Drug Administration

Study ID:

CGOG2001

NCT ID:

NCT01860144

Start Date:

June 2012

Completion Date:

December 2013

Related Keywords:

  • Metastatic Colorectal Cancer
  • bevacizumab
  • overall survival
  • adverse events
  • tumor resection rate
  • Colorectal Neoplasms

Name

Location